Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 9/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.56 |
| ▸ | PDE4A | P27815 | 4/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12413533 | 0.87 | ADORA2B (0.63) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL10535015 | 0.82 | ADORA2A (0.57) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL897035 | 0.81 | ADORA2B (0.55) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL2917584 | 0.81 | ADORA2B (0.55) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL7035609 | 0.79 | ADORA2B (0.52) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL7801074 | 0.76 | ADORA2B (0.56) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL3489064 | 0.75 | ADORA2A (0.55) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| 1-Methylxanthine SCHEMBL10996 | 0.75 | ADORA2B (1.00) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL5510062 | 0.75 | ADORA2B (0.64) | ADORA2BADORA2AADORA3PDE4APDE4B | |
| SCHEMBL2842234 | 0.75 | ADORA2B (0.55) | ADORA2BADORA2AADORA3PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 624 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090028830-A1 | Preparation of multipotent stem cells and the use thereof | LIU YUNG-HSIANG | 2009-01-29 | — | — | US | claimed |
| CN-101085983-A | Autologous stem cell, target cell transformed therefrom and its uses | YONGXIANG LIU (CN) | 2007-12-12 | — | — | CN | claimed |
| EP-0954565-B1 | ADIPOGENIC DIFFERENTIATION OF HUMAN MESENCHYMAL STEM CELLS | OSIRIS THERAPEUTICS INC (US) | 2006-10-11 | — | — | EP | claimed |
| WO-2004097009-A2 | METHOD TO IDENTIFY AGENTS THAT ACTIVATE OR INHIBIT IKKi | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | claimed |
| EP-0403139-B1 | Cell culture sytems and media | ORGANOGENESIS INC (US) | 1998-08-12 | — | — | EP | claimed |
| US-20260076966-A1 | METHOD OF INHIBITING TREM-1 | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-03-19 | — | — | US | disclosed |
| EP-3946349-B1 | SR-1903 FOR THE TREATMENT OF INFLAMMATORY, INNATE IMMUNE RESPONSE OR AUTOIMMUNE DISORDERS | UNIV FLORIDA (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20260049295-A1 | Targeting Nrip1 to Alleviate Metabolic Disease | UNIV MASSACHUSETTS (US) | 2026-02-19 | — | — | US | disclosed |
| US-12553039-B2 | Targeting Nrip1 to alleviate metabolic disease | UNIVERSITY OF MASSACHUSETTS (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4692301-A1 | CELL CHARACTERIZATION, TYPING AND IDENTIFICATION METHOD AND USE | Yigong Ruixin (Xiamen) Technology Co., Ltd (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035666-A1 | ENHANCED MSC PREPARATIONS | MESOBLAST INT SARL (CH) | 2026-02-05 | — | — | US | disclosed |
| US-20260016464-A1 | METHOD FOR CHARACTERIZING, TYPING AND IDENTIFYING CELLS AND USE THEREOF | YIGONG RUIXIN (XIAMEN) TECHNOLOGY CO., LTD (CN) | 2026-01-15 | — | — | US | disclosed |
| US-4764502-A | FERTILITY INHIBITION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1988-08-16 | — | — | US | disclosed |
| EP-0212489-A2 | Anabolic activity modulator and uses thereof | THE ROCKEFELLER UNIVERSITY (US) | 1987-03-04 | — | — | EP | disclosed |
| EP-0178841-A2 | Intragonadal regulatory protein | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1986-04-23 | — | — | EP | disclosed |
| US-4579865-A | ANTIISCHEMIC, HYPOGLYCEMIC AGENTS | USV PHARMACEUTICAL CORP. (US) | 1986-04-01 | — | — | US | disclosed |
| EP-0175005-A1 | 5,6,7-Quinoline carbamates | USV PHARMACEUTICAL CORPORATION (US) | 1986-03-26 | — | — | EP | disclosed |
| US-4547509-A | TREATMENT OF HYPERTRIGLYCERIDEMIA | USV PHARMACEUTICAL CORP. (US) | 1985-10-15 | — | — | US | disclosed |
| US-4530931-A | 8-Quinoline carbanilates for the inhibition of lipolysis | USV PHARMACEUTICAL CORP. (US) | 1985-07-23 | — | — | US | disclosed |
| US-4508828-A | Bioassay of parathyroid hormone | IMMUNO NUCLEAR CORPORATION (US) | 1985-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049295-A1 | Targeting Nrip1 to Alleviate Metabolic Disease | NR0B1, NR5A2, PLIN1 | ADORA2B 2121/4885ADORA2A 1131/4885ADORA3 1657/4885 |
| US-20260076966-A1 | METHOD OF INHIBITING TREM-1 | NR5A1, NR3C1, NR1H3 | ADORA2B 1270/4885ADORA2A 1279/4885ADORA3 339/4885 |
| US-12553039-B2 | Targeting Nrip1 to alleviate metabolic disease | SREBF1, NR1I2, NR5A2 | ADORA2B 2928/4885ADORA2A 1737/4885ADORA3 2651/4885 |
| US-20260016464-A1 | METHOD FOR CHARACTERIZING, TYPING AND IDENTIFYING CELLS AND USE THEREOF | ITGB4, HTR3D, EPCAM | ADORA2B 623/4885ADORA2A 902/4885ADORA3 625/4885 |
| US-20260035666-A1 | ENHANCED MSC PREPARATIONS | CD40, ICOS, CD63 | ADORA2B 1083/4885ADORA2A 386/4885ADORA3 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.